바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Next
e-Submission

Vol.68 No.1
Citation Share

18F-FDG Positron Emission Tomography in Patients with Concomitant Malignancy and Tuberculoma

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.68 no.1, pp.1-5
Jung Cheol Lee (University of Ulsan College of Medicine)

I-Nae Park (University of Ulsan College of Medicine)






Jung, C. L. , I-Nae, P. , & (2010). 18F-FDG Positron Emission Tomography in Patients with Concomitant Malignancy and Tuberculoma. Tuberculosis & Respiratory Diseases, 68(1), 1-5.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: To analyze the result of 18F-FDG positron emission tomography (PET) in patients with a concomitant malignancy and tuberculoma in a tuberculosis (TB)-endemic area. Methods: Twelve patients with a concomitant malignancy and tuberculoma, who underwent whole-body 18F-FDG PET, were evaluated retrospectively. The maximal standardized uptake values (SUVmax) of the malignancy and tuberculoma were compared. In 6 patients, 18F-FDG PET was repeated during the anti-TB treatment and the changes in SUVmax were analyzed. Results: Of the 12 patients, 10 were male. The mean age was 67.2±7.9 years. Tuberculomas were located in the lung (n=10) and lymph nodes (n=2), and tumors were located in the lung (n=6), colon (n=3), stomach (n=1),ovary (n=1) and liver (n=1). Although the mean SUVmax of malignant lesions was higher than that of tuberculomas (5.2±3.2 vs 3.5±2.0), the difference was not significant. In 4 patients, the SUVmax was higher in the tuberculoma than the tumor. After anti-TB treatment in 6 patients, the mean SUVmax of the tuberculomas decreased significantly,from 3.5±2.0 to 1.6±0.9 (p=0.028). Conclusion: In patients with a concomitant malignancy and tuberculoma, SUVmax alone could not differentiate between them. However, 18F-FDG PET may be useful in monitoring the response to anti-TB treatment.

keywords
Positron-Emission Tomography, Neoplasms, Tuberculoma

Reference

1.

1. Reske SN, Kotzerke J. FDG-PET for clinical use: results of the 3rd German Interdisciplinary Consensus Conference,“Onko-PET III”, 21 July and 19 September 2000.Eur J Nucl Med 2001;28:1707-23.

2.

2. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK,et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006;7:57-69.

3.

3. Sochocky S. Tuberculoma of the lung. Am Rev Tuberc 1958;78:403-10.

4.

4. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-21.

5.

5. Hofmeyr A, Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb) 2007;87:459-63.

6.

6. Yen RF, Chen KC, Lee JM, Chang YC, Wang J, Cheng MF, et al. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 2008;35:1305-15.

7.

7. An YS, Sun JS, Park KJ, Hwang SC, Park KJ, Sheen SS,et al. Diagnostic performance of 18F-FDG PET/CT for lymph node staging in patients with operable non-smallcell lung cancer and inflammatory lung disease. Lung 2008;186:327-36.

8.

8. Low SY, Eng P, Keng GH, Ng DC. Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis. Respirology 2006;1:84-9.

9.

9. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003;124:893-901.

10.

10. Park IN, Ryu JS, Shim TS. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 2008;33:1-3.

11.

11. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009;36:632-9.

12.

12. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009;53:4879-84.

13.

13. Lee HS, Oh JY, Lee JH, Yoo CG, Lee CT, Kim YW,et al. Response of pulmonary tuberculomas to anti-tuberculous treatment. Eur Respir J 2004;23:452-5.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy